Arbutus Biopharma Corporation
Arbutus Biopharma is a biotechnology company focused on discovering and developing therapeutics for chronic hepatitis B virus infection. The company pursues approaches intended to address viral persistence and improve outcomes for people living with hepatitis B. Its research includes RNA-based methods and other antiviral strategies, and the company collaborates with partners on selected technology and intellectual property programs. Arbutus is incorporated in British Columbia, Canada, while its principal executive offices are in Warminster, Pennsylvania, United States. Its common shares are registered on Nasdaq under ABUS.
Company at a glance
Corporate information
- Company entity
- Arbutus Biopharma Corporation
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.arbutusbio.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ABUS
RNA interference · antiviral therapeutics
hepatitis B · infectious diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Arbutus Biopharma is a biotechnology company focused on discovering and developing therapeutics for chronic hepatitis B virus infection. The company pursues approaches intended to address viral persistence and improve outcomes for people living with hepatitis B. Its research includes RNA-based methods and other antiviral strategies, and the company collaborates with partners on selected technology and intellectual property programs. Arbutus is incorporated in British Columbia, Canada, while its principal executive offices are in Warminster, Pennsylvania, United States. Its common shares are registered on Nasdaq under ABUS.
Business, technology & evidence
- SecuritiesNasdaq: ABUS
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Arbutus Biopharma Corporation ↗Arbutus Biopharma Corporation ·
- Official issuer and R&D disclosure · Arbutus Biopharma Corporation ↗Arbutus Biopharma Corporation ·
- Official issuer and R&D disclosure · Arbutus Biopharma Corporation ↗Arbutus Biopharma Corporation ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.